Ginkgo Bioworks Holdings (DNA) Net Income (2020 - 2026)
Ginkgo Bioworks Holdings' (DNA) quarterly Net Income came in at -$6.5 million in Q1 2026, up 14.63% YoY from -$5.7 million in Q1 2025, and up 91.92% on a QoQ basis from -$80.8 million in Q4 2025.
Ginkgo Bioworks Holdings (DNA) Net Income (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has 7 years of Net Income data on file, last reported at -$6.5 million in Q1 2026.
- Quarterly Net Income rose 14.63% year-over-year to -$6.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$228.3 million (up 41.27% YoY) and the FY2025 annual result came in at -$312.8 million, up 42.83% from the prior year.
- Net Income advanced to -$6.5 million in Q1 2026, from -$80.8 million in the prior quarter.
- In the past five years, Net Income ranged from a high of -$6.5 million in Q1 2026 to a low of -$670.6 million in Q2 2022.
- A 5-year average of -$222.5 million and a median of -$173.1 million in 2022 frame the typical range for Net Income.
- Annual changes were most pronounced in 2022 — Net Income tumbled 1131.22% — and 2025, when it soared 95.39%.
- Tracing DNA's Net Income over 5 years: stood at -$173.1 million in 2022, then fell by 22.31% to -$211.7 million in 2023, then surged by 49.2% to -$107.5 million in 2024, then gained by 24.91% to -$80.8 million in 2025, then surged by 91.92% to -$6.5 million in 2026.
- The last three Net Income figures came in at -$6.5 million (Q1 2026), -$80.8 million (Q4 2025), and -$80.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Ginkgo Bioworks Holdings | 432.60 Mn | 348.06 Mn | 18.44 Mn | 10.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.61 Mn |
| Mar 31, 2026 | -6.53 Mn |
| Dec 31, 2025 | -80.75 Mn |
| Sep 30, 2025 | -80.76 Mn |
| Jun 30, 2025 | -60.30 Mn |
| Mar 31, 2025 | -7.65 Mn |
| Dec 31, 2024 | -107.53 Mn |
| Sep 30, 2024 | -56.40 Mn |
| Jun 30, 2024 | -217.18 Mn |
| Mar 31, 2024 | -165.91 Mn |
| Dec 31, 2023 | -211.69 Mn |
| Sep 30, 2023 | -302.89 Mn |
| Jun 30, 2023 | -173.32 Mn |
| Mar 31, 2023 | -204.97 Mn |
| Dec 31, 2022 | -173.08 Mn |
| Sep 30, 2022 | -670.13 Mn |
| Jun 30, 2022 | -670.57 Mn |
| Mar 31, 2022 | -592.59 Mn |
| Dec 31, 2021 | -1.60 Bn |
| Sep 30, 2021 | -102.41 Mn |